This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Drug platforms			
Self-inactivating lentiviral vector with reduced leukemogenic potential for use in <i>x-linked severe combined immunodeficiency</i> (<i>IL2RG</i> ; <i>SCID1</i>) gene therapy	A self-inactivating lentiviral vector with reduced potential for leukemia could be useful for <i>SCID1</i> gene therapy. In a mouse model of <i>SCID1</i> , transplantation of vector-treated bone marrow cells restored lymphocyte development and function compared with transplantation of cells treated with mock control vector. In patient-isolated CD34 ⁺ bone marrow cells, the lentiviral vector increased T cell development compared with mock control vector. Next steps include submitting an IND to evaluate the vector in a clinical trial.	Work unpatented; licensing status not applicable	Zhou, S. <i>et al. Blood</i> ; published online May 10, 2010; doi:10.1182/blood-2009-10-250209 Contact: Sheng Zhou, St. Jude Children's Research Hospital, Memphis, Tenn. e-mail: sheng.zhou@stjude.org
SciBX 3(23); doi:10.1038/scibx.2010.717 Published online June 10, 2010			